Company Regeneron Pharmaceuticals, Inc. Sao Paulo
Equities
REGN34
BRREGNBDR005
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
96.5 BRL | +23.10% |
|
+2.12% | +41.68% |
25/06 | Argus Adjusts Price Target on Regeneron Pharmaceuticals to $1,170 From $1,060, Buy Rating Maintained | MT |
20/06 | Declaration of Voting Results by Regeneron Pharmaceuticals, Inc | CI |
Business Summary
- revenues from product sales (56.6%);
- revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%);
- other (3%): primarily revenues from sales of technology licenses and subcontracted research services.
At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Number of employees: 13,677
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Medicines
100.0
%
| 12,173 | 100.0 % | 13,117 | 100.0 % | +7.76% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
51.5
%
| 6,821 | 56.0 % | 6,754 | 51.5 % | -0.98% |
Rest of World
44.4
%
| 4,987 | 41.0 % | 5,827 | 44.4 % | +16.85% |
Other
4.1
%
| 365 | 3.0 % | 536 | 4.1 % | +46.84% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | 64 | 08/88/08 | |
Chief Executive Officer | 71 | 08/88/08 | |
Director of Finance/CFO | 53 | 01/03/01 | |
Melissa Lozner
CMP | Compliance Officer | - | 01/22/01 |
Bob McCowan
CTO | Chief Tech/Sci/R&D Officer | - | - |
Andrew Murphy
CTO | Chief Tech/Sci/R&D Officer | 66 | 01/99/01 |
Neil Stahl
CTO | Chief Tech/Sci/R&D Officer | 67 | 01/91/01 |
Patrice Gilooly
COO | Chief Operating Officer | - | 01/98/01 |
Chief Tech/Sci/R&D Officer | - | 01/19/01 | |
Mark Hudson
IRO | Public Communications Contact | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Christine Poon
BRD | Director/Board Member | 71 | 12/10/12 |
Chief Executive Officer | 71 | 08/88/08 | |
Michael Brown
BRD | Director/Board Member | 83 | 01/91/01 |
Joseph Goldstein
BRD | Director/Board Member | 83 | 01/91/01 |
George Sing
BRD | Director/Board Member | 74 | 08/88/08 |
Founder | 64 | 08/88/08 | |
Arthur Ryan
BRD | Director/Board Member | 81 | 01/03/01 |
N. Coles
BRD | Director/Board Member | 63 | 17/17/17 |
David Schenkein
BRD | Director/Board Member | 66 | 08/23/08 |
Bonnie Bassler
BRD | Director/Board Member | 61 | 12/16/12 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 10 | 1,818,146 | 0 | 0 | 78.42 % |
Stock B | 1 | 134,167,357 | 106,638,643 ( 79.48 %) | 25,800,000 ( 19.23 %) |
Company contact information
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
10591-6707, Tarrytown
+914 847 7000
http://www.regeneron.com![address Regeneron Pharmaceuticals, Inc.(REGN34)](https://cdn.zonebourse.com/static/address/57732092.png)
Group companies
Name | Category and Sector |
---|---|
Regeneron Ireland DAC
![]() Regeneron Ireland DAC BiotechnologyHealth Technology Part of Regeneron Pharmaceuticals, Inc., Regeneron Ireland DAC is a leading Irish biotechnology company that uses science to develop new medicines for patients. The company is located in Ireland. The company successfully manufactures a range of biopharmaceuticals for patients worldwide, including approved therapeutic proteins and those involved in clinical studies. |
Biotechnology
|
Sector
Sales per region
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.45% | 123B | |
+23.73% | 25.85B | |
-20.05% | 20.9B | |
-16.28% | 16.77B | |
-16.52% | 16.52B | |
-44.35% | 15.56B | |
+63.91% | 15.49B | |
+2.52% | 13.45B | |
+124.94% | 11.03B |
- Stock Market
- Equities
- REGN Stock
- REGN34 Stock
- Company Regeneron Pharmaceuticals, Inc.